Cargando…
Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial
BACKGROUND: Noninvasive remote patient management (RPM) in patients with heart failure (HF) has been shown to reduce the days lost due to unplanned cardiovascular hospital admissions and all-cause mortality in the Telemedical Interventional Management in Heart Failure II trial (TIM-HF2). The health...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622523/ https://www.ncbi.nlm.nih.gov/pubmed/34894273 http://dx.doi.org/10.1007/s00392-021-01980-2 |
_version_ | 1784821789212278784 |
---|---|
author | Sydow, Hanna Prescher, Sandra Koehler, Friedrich Koehler, Kerstin Dorenkamp, Marc Spethmann, Sebastian Westerhoff, Benjamin Wagner, Christoph J. Liersch, Sebastian Rebscher, Herbert Wobbe-Ribinski, Stefanie Rindfleisch, Heike Müller-Riemenschneider, Falk Willich, Stefan N. Reinhold, Thomas |
author_facet | Sydow, Hanna Prescher, Sandra Koehler, Friedrich Koehler, Kerstin Dorenkamp, Marc Spethmann, Sebastian Westerhoff, Benjamin Wagner, Christoph J. Liersch, Sebastian Rebscher, Herbert Wobbe-Ribinski, Stefanie Rindfleisch, Heike Müller-Riemenschneider, Falk Willich, Stefan N. Reinhold, Thomas |
author_sort | Sydow, Hanna |
collection | PubMed |
description | BACKGROUND: Noninvasive remote patient management (RPM) in patients with heart failure (HF) has been shown to reduce the days lost due to unplanned cardiovascular hospital admissions and all-cause mortality in the Telemedical Interventional Management in Heart Failure II trial (TIM-HF2). The health economic implications of these findings are the focus of the present analyses from the payer perspective. METHODS AND RESULTS: A total of 1538 participants of the TIM-HF2 randomized controlled trial were assigned to the RPM and Usual Care group. Health claims data were available for 1450 patients (n = 715 RPM group, n = 735 Usual Care group), which represents 94.3% of the original TIM-HF2 patient population, were linked to primary data from the study documentation and evaluated in terms of the health care cost, total cost (accounting for intervention costs), costs per day alive and out of hospital (DAOH), and cost per quality-adjusted life year (QALY). The average health care costs per patient year amounted to € 14,412 (95% CI 13,284–15,539) in the RPM group and € 17,537 (95% CI 16,179–18,894) in the UC group. RPM led to cost savings of € 3125 per patient year (p = 0.001). After including the intervention costs, a cost saving of € 1758 per patient year remained (p = 0.048). CONCLUSION: The additional noninvasive telemedical interventional management in patients with HF was cost-effective compared to standard care alone, since such intervention was associated with overall cost savings and superior clinical effectiveness. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9622523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-96225232022-11-02 Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial Sydow, Hanna Prescher, Sandra Koehler, Friedrich Koehler, Kerstin Dorenkamp, Marc Spethmann, Sebastian Westerhoff, Benjamin Wagner, Christoph J. Liersch, Sebastian Rebscher, Herbert Wobbe-Ribinski, Stefanie Rindfleisch, Heike Müller-Riemenschneider, Falk Willich, Stefan N. Reinhold, Thomas Clin Res Cardiol Original Paper BACKGROUND: Noninvasive remote patient management (RPM) in patients with heart failure (HF) has been shown to reduce the days lost due to unplanned cardiovascular hospital admissions and all-cause mortality in the Telemedical Interventional Management in Heart Failure II trial (TIM-HF2). The health economic implications of these findings are the focus of the present analyses from the payer perspective. METHODS AND RESULTS: A total of 1538 participants of the TIM-HF2 randomized controlled trial were assigned to the RPM and Usual Care group. Health claims data were available for 1450 patients (n = 715 RPM group, n = 735 Usual Care group), which represents 94.3% of the original TIM-HF2 patient population, were linked to primary data from the study documentation and evaluated in terms of the health care cost, total cost (accounting for intervention costs), costs per day alive and out of hospital (DAOH), and cost per quality-adjusted life year (QALY). The average health care costs per patient year amounted to € 14,412 (95% CI 13,284–15,539) in the RPM group and € 17,537 (95% CI 16,179–18,894) in the UC group. RPM led to cost savings of € 3125 per patient year (p = 0.001). After including the intervention costs, a cost saving of € 1758 per patient year remained (p = 0.048). CONCLUSION: The additional noninvasive telemedical interventional management in patients with HF was cost-effective compared to standard care alone, since such intervention was associated with overall cost savings and superior clinical effectiveness. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2021-12-11 2022 /pmc/articles/PMC9622523/ /pubmed/34894273 http://dx.doi.org/10.1007/s00392-021-01980-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Sydow, Hanna Prescher, Sandra Koehler, Friedrich Koehler, Kerstin Dorenkamp, Marc Spethmann, Sebastian Westerhoff, Benjamin Wagner, Christoph J. Liersch, Sebastian Rebscher, Herbert Wobbe-Ribinski, Stefanie Rindfleisch, Heike Müller-Riemenschneider, Falk Willich, Stefan N. Reinhold, Thomas Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title | Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title_full | Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title_fullStr | Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title_full_unstemmed | Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title_short | Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial |
title_sort | cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the tim-hf2 trial |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622523/ https://www.ncbi.nlm.nih.gov/pubmed/34894273 http://dx.doi.org/10.1007/s00392-021-01980-2 |
work_keys_str_mv | AT sydowhanna costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT preschersandra costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT koehlerfriedrich costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT koehlerkerstin costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT dorenkampmarc costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT spethmannsebastian costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT westerhoffbenjamin costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT wagnerchristophj costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT lierschsebastian costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT rebscherherbert costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT wobberibinskistefanie costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT rindfleischheike costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT mullerriemenschneiderfalk costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT willichstefann costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial AT reinholdthomas costeffectivenessofnoninvasivetelemedicalinterventionalmanagementinpatientswithheartfailurehealtheconomicanalysisofthetimhf2trial |